{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:54:27Z","timestamp":1783976067615,"version":"3.55.0"},"reference-count":112,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Land Schleswig-Holstein"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The mitochondrial amidoxime-reducing component (mARC) is the most recently discovered molybdoenzyme in humans after sulfite oxidase, xanthine oxidase and aldehyde oxidase. Here, the timeline of mARC\u2019s discovery is briefly described. The story begins with investigations into N-oxidation of pharmaceutical drugs and model compounds. Many compounds are N-oxidized extensively in vitro, but it turned out that a previously unknown enzyme catalyzes the retroreduction of the N-oxygenated products in vivo. After many years, the molybdoenzyme mARC could finally be isolated and identified in 2006. mARC is an important drug-metabolizing enzyme and N-reduction by mARC has been exploited very successfully for prodrug strategies, that allow oral administration of otherwise poorly bioavailable therapeutic drugs. Recently, it was demonstrated that mARC is a key factor in lipid metabolism and likely involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The exact link between mARC and lipid metabolism is not yet fully understood. Regardless, many now consider mARC a potential drug target for the prevention or treatment of liver diseases. This article focusses on discoveries related to mammalian mARC enzymes. mARC homologues have been studied in algae, plants and bacteria. These will not be discussed extensively here.<\/jats:p>","DOI":"10.3390\/molecules28124713","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T02:00:45Z","timestamp":1686621645000},"page":"4713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The History of mARC"],"prefix":"10.3390","volume":"28","author":[{"given":"Bernd","family":"Clement","sequence":"first","affiliation":[{"name":"Pharmazeutisches Institut, Christian-Albrechts-Universit\u00e4t zu Kiel, Gutenbergstra\u00dfe 76, 24118 Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6931-1841","authenticated-orcid":false,"given":"Michel","family":"Struwe","sequence":"additional","affiliation":[{"name":"Pharmazeutisches Institut, Christian-Albrechts-Universit\u00e4t zu Kiel, Gutenbergstra\u00dfe 76, 24118 Kiel, Germany"},{"name":"Zoologisches Institut\u2014Strukturbiologie, Zentrum f\u00fcr Biochemie und Molekularbiologie, Christian-Albrechts-Universit\u00e4t zu Kiel, Am Botanischen Garten 1\u22129, 24118 Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/00498258109045872","article-title":"Metabolism of promethazine In vitro. Identificaton of N-oxidized products","volume":"11","author":"Clement","year":"1981","journal-title":"Xenobiotica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/00498258309052286","article-title":"The N-oxidation of benzamidines in vitro","volume":"13","author":"Clement","year":"1983","journal-title":"Xenobiotica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3109\/00498258709043973","article-title":"Characteristics of the microsomal N-hydroxylation of benzamidine to benzamidoxime","volume":"17","author":"Clement","year":"1987","journal-title":"Xenobiotica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ardp.19843171106","article-title":"In vitro studies on the microsomal N-oxidation of N-substituted benzamidines","volume":"317","author":"Clement","year":"1984","journal-title":"Arch. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0009-2797(73)90004-5","article-title":"Differentiation of various types of biological oxidation of nitrogen in organic compounds","volume":"289","author":"Gorrod","year":"1973","journal-title":"Chem. Biol. Interact."},{"key":"ref_6","unstructured":"Gorrod, J. (1978). Biological Oxidation of Nitrogen, Elsevier."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/ardp.19873200717","article-title":"Untersuchungen zur in vitro N-Oxygenierung N-tert.alkylsubstituierter Benzamidine","volume":"320","author":"Clement","year":"1987","journal-title":"Arch. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/0006-2952(87)90622-8","article-title":"Hepatic microsomal N-demethylation of N-methylbenzamidine: N-dealkylation vs","volume":"36","author":"Clement","year":"1987","journal-title":"N-oxygenation of amidines. Biochem. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1016\/0006-2952(88)90347-4","article-title":"Mechanism of the microsomal N-hydroxylation of para-substituted benzamidines","volume":"37","author":"Clement","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ardp.19863191102","article-title":"In-vitro-Untersuchungen zur mikrosomalen N-Oxidation einiger Guanidine","volume":"319","author":"Clement","year":"1986","journal-title":"Arch. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/00498259309059371","article-title":"In vitro oxygenation of N,N\u2019-diphenylguanidines","volume":"23","author":"Clement","year":"1993","journal-title":"Xenobiotica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3109\/00498259409043269","article-title":"Cytochrome P450-dependent N-hydroxylation of an aminoguanidine (amidinohydrazone) and microsomal retroreduction of the N-hydroxylated product","volume":"24","author":"Clement","year":"1994","journal-title":"Xenobiotica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ardp.19933260106","article-title":"Microsomal N-oxygenation of adenine to adenine 1-N-oxide","volume":"326","author":"Clement","year":"1993","journal-title":"Arch. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1515\/DMDI.1989.7.1.87","article-title":"Structural requirements of microsomal N-oxygenations derived from studies on amidines","volume":"7","author":"Clement","year":"1989","journal-title":"Drug Metab. Drug Interact."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Najmi, A.A., Bischoff, R., and Permentier, H.P. (2022). N-Dealkylation of amines. Molecules, 27.","DOI":"10.3390\/molecules27103293"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/dmd.113.055202","article-title":"Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy caucasians","volume":"42","author":"Ott","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01797915","article-title":"Detoxification pathways in the liver","volume":"14","author":"Grant","year":"1991","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1021\/tx000105f","article-title":"Phase 2 metabolites of N-hydroxylated amidines (amidoximes):\u2009 synthesis, In vitro formation by pig hepatocytes, and mutagenicity testing","volume":"14","author":"Clement","year":"2001","journal-title":"Chem. Res. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1124\/dmd.105.004572","article-title":"Metabolism of N-hydroxyguanidines (N-hydroxydebrisoquine) in human and porcine hepatocytes: Reduction and formation of glucuronides","volume":"33","author":"Froehlich","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ardp.19893220710","article-title":"Biotransformation des Benzamidins und des Benzamidoxims durch mikrosomale Enzyme vom Kaninchen","volume":"322","author":"Clement","year":"1989","journal-title":"Arch. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ardp.19883211228","article-title":"Enzymatic reduction of benzamidoxime to benzamidoxine","volume":"321","author":"Clement","year":"1988","journal-title":"Arch. Pharm."},{"key":"ref_22","first-page":"559","article-title":"Reduction of a benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro","volume":"43","author":"Hauptmann","year":"1988","journal-title":"Pharmazie"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ardp.19933261008","article-title":"Biotransformations of benzamidine and benzamidoxime in vivo","volume":"326","author":"Clement","year":"1993","journal-title":"Arch. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1128\/AAC.34.9.1678","article-title":"Metabolic N-hydroxylation of pentamidine in vitro","volume":"34","author":"Berger","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","first-page":"1009","article-title":"Amidoximes of pentamidine: Synthesis, trypanocidal and leishmanicidal activity","volume":"35","author":"Clement","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ardp.19923250114","article-title":"Reduction of amidoxime derivatives to pentamidine in vivo","volume":"325","author":"Clement","year":"1992","journal-title":"Arch. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2014.10.032","article-title":"In vivo SPECT imaging of [123I]-labeled pentamidine prodrugs for the treatment of human African trypanosomiasis, pharmacokinetics, and bioavailability studies in rats","volume":"477","author":"Cohrs","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1081\/DMR-120005643","article-title":"Reduction of N-hydroxylated compounds: Amidoximes (N-hydroxyamidines) as pro-drugs of amidines","volume":"34","author":"Clement","year":"2002","journal-title":"Drug Metab. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1021\/jm701259d","article-title":"N,N\u2032-Dihydroxyamidines: A new prodrug principle to improve the oral bioavailability of amidines","volume":"50","author":"Reeh","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/cmdc.201100422","article-title":"New prodrugs of the antiprotozoal drug pentamidine","volume":"6","author":"Kotthaus","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/cmdc.200900233","article-title":"The peptidylglycine alpha-amidating monooxygenase (PAM): A novel prodrug strategy for amidoximes and N-hydroxyguanidines?","volume":"4","author":"Schade","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_32","first-page":"196","article-title":"Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?","volume":"8","author":"Zikria","year":"2009","journal-title":"Discov. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-6147(00)01885-X","article-title":"Novel approaches to the treatment of thrombosis","volume":"23","author":"Gresele","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1515\/bchm3.1992.373.2.491","article-title":"Interactions of thrombin with benzamidine-based inhibitors","volume":"373","author":"Vieweg","year":"1992","journal-title":"Biol. Chem. Hoppe Seyler"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/oxfordjournals.jbchem.a129540","article-title":"Proteolytic Enzymes: VI. aromatic amidines as competitive inhibitors of trypsin","volume":"69","author":"Tanizawa","year":"1971","journal-title":"J. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1021\/acs.jmedchem.5b00812","article-title":"Fragment binding ban be either more enthalpy-driven or entropy-driven: Crystal structures and residual hydration patterns suggest why","volume":"58","author":"Betz","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/pro.3280","article-title":"Improvements to the APBS biomolecular solvation software suite","volume":"27","author":"Jurrus","year":"2018","journal-title":"Protein Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1021\/jm9509298","article-title":"Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines","volume":"39","author":"Weller","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2125.1999.00931.x","article-title":"Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers","volume":"47","author":"Wittke","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0960-894X(02)00921-6","article-title":"Design and synthesis of factor Xa inhibitors and their prodrugs","volume":"13","author":"Song","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1016\/j.bmcl.2008.07.009","article-title":"Orally active factor Xa inhibitors: Investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy","volume":"18","author":"Uchida","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: Intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/dmd.31.5.645","article-title":"Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug","volume":"31","author":"Clement","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cully, M. (2017). Milestone 9: Ximelagatran sets the stage for NOACs. Nat. Rev. Cardiol.","DOI":"10.1038\/nrcardio.2017.179"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2146\/ajhp100348","article-title":"Dabigatran etexilate: A novel oral direct thrombin inhibitor","volume":"68","author":"Blommel","year":"2011","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_49","unstructured":"Clement, B., Kotthaus, J., Kotthaus, J., and Schade, D. (2017). Dabigatran-Amidoximester als Prodrugs und ihre Verwendung als Arzneimittel (EP 2550966 B1). (EP 2773347 B1), EU Patent."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/00498254.2013.767481","article-title":"Activation of the anti-cancer agent upamostat by the mARC enzyme system","volume":"43","author":"Froriep","year":"2013","journal-title":"Xenobiotica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2022.12.003","article-title":"A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19","volume":"128","author":"Plasse","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/jps.24508","article-title":"Zanamivir amidoxime- and N-hydroxyguanidine-based prodrug approaches to tackle poor oral bioavailability","volume":"104","author":"Schade","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/jm401492x","article-title":"Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A","volume":"57","author":"Schade","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/cmdc.202000349","article-title":"A novel prodrug of a nNOS inhibitor with improved pharmacokinetic potential","volume":"15","author":"Maccallini","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0003-9861(74)90107-6","article-title":"Properties of a NADH-dependent N-hydroxy amine reductase isolated from pig liver microsomes","volume":"162","author":"Kadlubar","year":"1974","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/dmd.104.002972","article-title":"Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime","volume":"33","author":"Andersson","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0003-9861(68)90349-4","article-title":"Reduction of hydroxylamine by rat liver mitochondria","volume":"124","author":"Bernheim","year":"1968","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0003-9861(69)90300-2","article-title":"The hydroxylamine reductase of mitochondria","volume":"134","author":"Bernheim","year":"1969","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"19615","DOI":"10.1074\/jbc.272.31.19615","article-title":"Isolation and characterization of the protein components of the liver microsomal O2-insensitive NADH-benzamidoxime reductase","volume":"272","author":"Clement","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_60","first-page":"48","article-title":"Identification of stearoyl CoA desaturase as the enzyme responsible for the reduction of ximelagatran\/N-hydroxymelagatran and benzamidoxime in adipocytes","volume":"37","author":"Johansson","year":"2005","journal-title":"Drug Metab. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/00498250802109199","article-title":"Involvement of stearoyl-CoA desaturase in the reduction of amidoxime prodrugs","volume":"38","author":"Reh","year":"2008","journal-title":"Xenobiotica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"34796","DOI":"10.1074\/jbc.M607697200","article-title":"Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme","volume":"281","author":"Havemeyer","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_63","first-page":"55","article-title":"MOSC domains: Ancient, predicted sulfur-carrier domains, present in diverse metal-sulfur cluster biosynthesis proteins including molybdenum cofactor sulfurases","volume":"207","author":"Anantharaman","year":"2002","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12743","DOI":"10.1038\/s41598-022-17104-3","article-title":"Gene Updater: A web tool that autocorrects and updates for Excel misidentified gene names","volume":"12","author":"Koh","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Mendel, R.R. (2022). The history of the molybdenum cofactor\u2014A personal view. Molecules, 27.","DOI":"10.3390\/molecules27154934"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.1021\/jm8010417","article-title":"The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs","volume":"51","author":"Gruenewald","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"37847","DOI":"10.1074\/jbc.M110.169532","article-title":"Biochemical and spectroscopic characterization of the human Mitochondrial Amidoxime Reducing Components hmARC-1 and hmARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes","volume":"285","author":"Wahl","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1021\/acs.jmedchem.9b01483","article-title":"Drug metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid assay and identification of new substrates","volume":"63","author":"Indorf","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.elecom.2017.10.003","article-title":"Human mitochondrial amidoxime reducing component (mARC): An electrochemical method for identifying new substrates and inhibitors","volume":"84","author":"Kalimuthu","year":"2017","journal-title":"Electrochem. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1021\/acs.analchem.2c02232","article-title":"Enzyme electrode biosensors for N-hydroxylated prodrugs incorporating the mitochondrial Amidoxime Reducing Component","volume":"94","author":"Zapiter","year":"2022","journal-title":"Anal. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"42795","DOI":"10.1074\/jbc.M112.419424","article-title":"The Mitochondrial Amidoxime-Reducing Component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane","volume":"287","author":"Klein","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20228","DOI":"10.1074\/jbc.M113.474916","article-title":"The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells","volume":"288","author":"Plitzko","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1124\/dmd.116.071845","article-title":"Defining the role of the NADH-cytochrome-b5 reductase 3 in the Mitochondrial Amidoxime Reducing Component enzyme system","volume":"44","author":"Plitzko","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11958","DOI":"10.1073\/pnas.1808576115","article-title":"Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes","volume":"115","author":"Kubitza","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1107\/S2053230X18006921","article-title":"T4 lysozyme-facilitated crystallization of the human molybdenum cofactor-dependent enzyme mARC","volume":"74","author":"Kubitza","year":"2018","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201402437","article-title":"Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: Consequences for the prodrug concept \u201camidoximes instead of amidines\u201d","volume":"10","author":"Bauch","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1042\/BJ20100960","article-title":"Reduction of N(omega)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC)","volume":"433","author":"Kotthaus","year":"2011","journal-title":"Biochem. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/cmdc.201402127","article-title":"The mitochondrial amidoxime reducing component (mARC): Involvement in metabolic reduction of N-oxides, oximes and N-hydroxyamidinohydrazones","volume":"9","author":"Jakobs","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1124\/dmd.110.032813","article-title":"Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC","volume":"28","author":"Havemeyer","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1124\/dmd.118.082453","article-title":"The involvement of the Mitochondrial Amidoxime Reducing Component (mARC) in the reductive metabolism of hydroxamic acids","volume":"46","author":"Ginsel","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_81","first-page":"1396","article-title":"Detoxification of trimethylamine N-oxide by the Mitochondrial Amidoxime Reducing Component mARC","volume":"46","author":"Schneider","year":"2018","journal-title":"Chem. Res. Toxicol."},{"key":"ref_82","unstructured":"Wermuth, C.G., Aldous, D., Raboisson, P., and Rognan, D. (2015). The Practice of Medicinal Chemistry, Academic Press. [4th ed.]."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2958.2008.06128.x","article-title":"YcbX and yiiM, two novel determinants for resistance of Escherichia coli to N-hydroxylated base analogues","volume":"68","author":"Kozmin","year":"2008","journal-title":"Mol. Microbiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1021\/tx300298m","article-title":"The Mitochondrial Amidoxime Reducing Component (mARC) is involved in detoxification of N-hydroxylated base analogues","volume":"25","author":"Krompholz","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10126","DOI":"10.1074\/jbc.M115.640052","article-title":"The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine","volume":"290","author":"Plitzko","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1021\/tx500174u","article-title":"Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC)","volume":"27","author":"Ott","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"ref_89","first-page":"117","article-title":"Mechanism of N-hydroxyacetylarylamine mutagenicity in the Salmonella test system: Metabolic activation of N-hydroxyphenacetin by liver and kidney fractions from rat, mouse, hamster, and man","volume":"18","author":"Peter","year":"1980","journal-title":"Mol. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"10345","DOI":"10.1074\/jbc.M114.555177","article-title":"Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2","volume":"289","author":"Tejero","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.freeradbiomed.2017.10.042","article-title":"Oxygen inhibits nitrite reduction to nitric oxide by the molybdenum-fependent mARC-2 enzyme","volume":"112","author":"Cecco","year":"2017","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1038\/s41388-020-01417-6","article-title":"A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27","volume":"39","author":"Wu","year":"2020","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/biof.1362","article-title":"The molybdenum cofactor enzyme mARC: Moonlighting or promiscuous enzyme?","volume":"43","author":"Llamas","year":"2017","journal-title":"Biofactors"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"790093","DOI":"10.3389\/fgene.2021.790093","article-title":"Downregulation of MARC2 promotes immune escape and is associated with immunosuppression of hepatocellular carcinoma","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Emdin, C.A., Haas, M.E., Khera, A.V., Aragam, K., Chaffin, M., Klarin, D., Hindy, G., Jiang, L., Wei, W.Q., and Feng, Q. (2020). A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1009503"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1074\/jbc.M111.328237","article-title":"Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria","volume":"287","author":"Neve","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Neve, E.P., Kofeler, H., Hendriks, D.F., Nordling, A., Gogvadze, V., Mkrtchian, S., Naslund, E., and Ingelman-Sundberg, M. (2015). Expression and function of mARC: Roles in lipogenesis and metabolic activation of ximelagatran. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138487"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.1074\/jbc.RA119.007606","article-title":"Mitochondrial amidoxime-reducing component 2 (mARC2) has a significant role in N-reductive activity and energy metabolism","volume":"294","author":"Rixen","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_99","unstructured":"Gladwin, M., Sparacino-Watkins, C.E., and Jurczak, M. (2019). Method of Treating Insulin Resistance. (US20190160154), U.S. Patent."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/hep4.1955","article-title":"Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms","volume":"8","author":"Hudert","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/hep4.1984","article-title":"Letter to the editor: The clinically relevant MTARC1 p.Ala165Thr variant impacts neither the fold nor active site architecture of the human mARC1 protein","volume":"6","author":"Struwe","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/hep4.2009","article-title":"Reply","volume":"6","author":"Hudert","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.medj.2021.04.011","article-title":"A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes","volume":"2","author":"Schneider","year":"2021","journal-title":"Med"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","article-title":"Multiomics study of nonalcoholic fatty liver disease","volume":"54","author":"Sveinbjornsson","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/gepi.22392","article-title":"Genome-wide association analysis of serum alanine and aspartate aminotransferase, and the modifying effects of BMI in 388k European individuals","volume":"54","author":"Gao","year":"2021","journal-title":"Genet. Epidemiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1053\/j.gastro.2020.06.014","article-title":"Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1","volume":"159","author":"Innes","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep4.1805","article-title":"Genome-wide association study of NAFLD using electronic health records","volume":"6","author":"Fairfield","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100693","DOI":"10.1016\/j.jhepr.2023.100693","article-title":"Hepatocyte mARC1 promotes fatty liver disease","volume":"5","author":"Lewis","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/08998280.2005.11928037","article-title":"Ximelagatran (Exanta): Alternative to warfarin?","volume":"18","author":"Vaughan","year":"2005","journal-title":"Bayl. Univ. Med Cent. Proc."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1124\/dmd.105.005249","article-title":"Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2S)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperid inyl]oxy]-acetic acid)","volume":"33","author":"Clement","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Tejada-Jimenez, M., Chamizo-Ampudia, A., Calatrava, V., Galvan, A., Fernandez, E., and Llamas, A. (2018). From the eukaryotic molybdenum cofactor biosynthesis to the moonlighting enzyme mARC. Molecules, 23.","DOI":"10.3390\/molecules23123287"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/12\/4713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:22Z","timestamp":1760126002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/12\/4713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":112,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["molecules28124713"],"URL":"https:\/\/doi.org\/10.3390\/molecules28124713","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}